Novartis Office of Grants & Education
Request for Proposal (RFP) - Professional Medical Education

The Novartis Office of Grants & Education (NOGE) supports independent high-quality medical educational programs which provide fair-balanced, evidence-based, current scientific information to healthcare professionals in order to improve patient care. Activities should have an educational focus, be independent of commercial bias and be non-promotional in nature. NOGE will perform these duties in compliance with laws, regulations and guidelines as established by the ACCME, PhRMA Code, OIG, other regulatory agencies and in compliance with Novartis guidelines and policies.

Key Dates:	RFP Issued: June 17, 2025 ***Applications Due to Novartis: September 5, 2025 by 5 PM EST*** Notification of Grant Decisions: Mid-October 2025 Educational Programming Starts: Q4 2025 – Q1 2026
Therapeutic Area:	Spinal Muscular Atrophy
Educational Need:	**Emerging data, newly available treatments and more readily available newborn screening have changed the face of care for spinal muscular atrophy (SMA)** • As an autosomal recessive disease, SMA is the leading genetic cause of death in infants. One in fifty parents are carriers of the impacted gene with an occurrence of approximately one in ten thousand live births.[1] • Clinical results indicating the benefit of currently approved treatments provide strong support for the widespread use of neonatal screening.[2] • The burden of disease remains substantial. Without early treatment, SMA leads to respiratory failure, feeding difficulties, and mobility loss – resulting in frequent hospitalizations, complex medical needs, and long-term reliance on assistive technologies. This places emotional and financial burden on families, who serve as full-time caregivers, and contributes to high healthcare utilization and cost. [3] • Recent advances in NBS and the emergence of FDA approved treatments have dramatically changed the landscape of care for this devastating condition.[3] • However, gaps remain in access to screening and timely treatment, leading to preventable delays in care. Expanded education is needed to address the burden of disease, promote equitable access to NBS, and ensure rapid diagnosis and intervention to improve long-term outcomes for all affected infants.[3]
Geographic Scope:	Primary geography of interest: United States (National, Regional, and/or Local) Note: Applications for this RFP must be US-focused for the audience, expert faculty, educational needs, and standards of care. Proposals that include collaborations with third parties, including (but not limited to) community-based hospitals, medical societies, health education companies/centers, not-for-profit organizations, and academic institutions, are encouraged, as appropriate.
Project Description:	NOGE has identified the need for innovative continuing medical education programs that strive to optimize patient outcomes through education on:

	• Diagnosis and Disease Progression - Understand the basis for diagnosis of SMA and expected disease progression based on subtype and presentation. • Guidelines, Goals and Evidence-Based Medicine - Identify current recommendations for care and apply evidence-based strategies to treat patients with SMA. • Coordination and Transition of Care - Utilize shared decision making and the multidisciplinary team to effectively treat patients with SMA. Encourage effective management of transitions of care between pediatric and adult patient care. • Patient-Reported Outcomes - Increase knowledge of patient-reported outcomes, activities of daily living assessments, measurement of caregiver burden, and other quality of life measurements to gauge disease progression and response to treatment. • Clinical Trials and Treatment - Differentiate between current and emerging treatments with the most up to date, evidence-based efficacy and safety data for treatment of patients with SMA. • Gene Therapy - Broaden understanding of gene therapies including how to minimize barriers to use. • Scales and Assessments - Educate on the use of scales and assessments to assess disease progression and guide treatment selection. NOGE is seeking to support innovative and engaging programs including, but not limited to, the following: • On demand web-based education • Case-based learning opportunities Note: Program placement is independent of Novartis. Program placement should reflect appropriate reach efforts.
Target Audience:	Healthcare providers who are involved in the care of patients with SMA: Neurologists, NP/PAs, RNs, Neurology Fellows, Physical Therapists, Occupational Therapists, Speech Therapists, Managed Care Clinicians, Primary Care Clinicians, Pharmacists, Neurology Residents, Maternal Fetal Medicine Specialists Educational providers should include target number of participants. Further, please include details on proposed audience recruitment. Please note: Novartis will not participate in the distribution of invitations to the CME/CE event.
Available Funding:	Single-support or multi-support initiatives may be funded; up to $200,000 total support is available for 2025.
Submission Requirements:	If working with an Accredited Provider and/or Educational Partner, they should be listed in the Novartis grant application. Grant requests must be submitted by the Office of CME (if from an Academic Institution/Hospital) via the Novartis Grants Central Station website: www.ngcs.novartis.com *by 5 PM EST on September 5, 2025 to be considered*.

	The grant application should include “RFP Response” within the Program Title [example: “RFP Response: *Program Title*”]. Proposals that include collaborations with third parties, including (but not limited to) community-based hospitals, medical societies, health education companies/centers, not-for-profit organizations, and academic institutions, are encouraged, as appropriate.

For grant request submission information, FAQs, and eligibility criteria, please visit:
https://www.novartis.us/corporate-responsibility/external-funding

If you have any questions regarding this RFP, you should only contact NOGE at grants.office@novartis.com
[Please title the subject of your email: “RFP Hyperlipidemia”].

References

1. Lunn, Mitchell R., and Ching H. Wang. "Spinal muscular atrophy." *The Lancet* 371.9630 (2008): 2120-2133.
2. Mercuri, Eugenio, et al. "Spinal muscular atrophy." *Nature Reviews Disease Primers* 8.1 (2022): 52.
3. Mouchet J, Roumpanis S, Gaki E, et al. “Disease Burden of Spinal Muscular Atrophy: A Comparative Cohort Study Using Insurance Claims Data in the USA.” *J Neuromuscul Dis*. 2023;10(1):41-53. doi:10.3233/JND-210764